PharmaNet Development Group Inc. (NASDAQ:SFCC)
Industry: Services

Listed 57 Consecutive Market Days. On List as of 12/15/2005 Through 03/10/2006

SFBC International, Inc. (SFBC) is a global drug development services company, providing a range of both early and late-stage clinical drug development services to branded pharmaceutical, biotechnology and generic drug and medical device companies around the world. The Company conducts its operations in two segments: early stage and late stage clinical development. Early stage consists primarily of SFBC's Phase I clinical trial facilities, bioanalytical laboratories and clinical laboratories. Late stage consists of its subsidiary, PharmaNet, Inc., which primarily provides late Phase II through Phase IV services. Early Stage Clinical Development Services The Company's early stage clinical development services include developing study designs, recruiting and screening study participants, conducting early-stage clinical trials, and collecting and reporting to its clients the clinical data collected during the course of its clinical trials. SFBC operates four early-stage clinical trial facilities located in Miami and Ft. Myers, Florida and in Quebec City and Montreal in Canada. The Company's Canadian operations (excluding PharmaNet) accounted for approximately 26% of its consolidated direct revenue during the year ended December 31, 2005. SFBC's Miami facility, which formerly had a capacity of 675 beds and housed its corporate headquarters, has been reduced to 350 beds due to changes since November 2005. SFBC may assist its clients in preparing the study protocol, designing case report forms and conducting any necessary clinical trial audit functions. The Company also collects data throughout a clinical trial and enters it onto case report forms according to Good Clinical Practices (GCP) guidelines in order to meet its clients' needs and the United States Food and Drug Administration (FDA) or other regulatory requirements identified in the study protocol. The Company's data management services also provide its clients with statistical analysis, medical report writing and assistance with regulatory submissions. The Company provides bioanalytical laboratory services primarily in support of early clinical trials at its facilities located in Quebec City and Toronto, Canada; Princeton, New Jersey, Philadelphia, Pennsylvania, and Barcelona, Spain. Its bioanalytical laboratories provide bioanalytical support for preclinical studies, drug discoveries, early clinical trials studies, bioequivalence studies, bioavailability studies and drug metabolism studies. During the clinical trial process, the Company conducts laboratory analysis on various biological specimens to determine the quantity of a drug present in each specimen. SFBC formats and presents the data resulting from this process to its clients for their use and interpretation. The Company's Canadian facilities have approximately 318 beds and include Anapharm Inc., SFBC's principal Canadian subsidiary. These facilities primarily service the generic drug industry, although approximately 19% of Anapharm's revenue comes from branded pharmaceutical and biotechnology companies. Late Stage Clinical Development Services Through PharmaNet, which the Company acquired in December 2004, provides late-stage clinical development services for studies, including clinical operations, data management and biostatistics, regulatory, medical and scientific affairs, and consulting. SFBC provides an array of services in support of these trials, including planning, protocol/case report form design, site selection, monitoring and project management, software systems development and support, quality control/assurance, global safety and pharmacovigilance, and post-FDA approval development services. The Company's late stage clinical development services cover most therapeutic areas with focus in oncology, neurosciences, cardiovascular, respiratory, renal/urinary, gastro-intestinal, infectious disease, dermatology, endocrinology, musculoskeletal, ophthalmology and women's health. PharmaNet accounted for approximately 47% of the Company's direct revenue in 2005. SFBC provides late st

Current Quote*
Last: $Unk
Change: 0.000
Book: $Unk
Volume: Unk

As Of: 10/07 00:00 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol SFCC

  • No BuyIns.Net Alerts Available for SFCC

Graphs for SFCC


3 Month Graph


6 Month Graph


1 Year Graph